Investor Relations

OPKO Licensee TESARO Receives FDA Approval for VARUBI™ (rolapitant) more »

OPKO Letter to Shareholders more »

OPKO Health to Be Present at the Barrington Research Fall Investment Conference more »

OPKO Completes Acquisition of Bio-Reference Laboratories more »

Investor FAQs